Long-term results with a slow-release gonadotrophin-releasing hormone agonist in central precocious puberty. Dutch-German Precocious Puberty Study Group.

Oostdijk W, Drop SL, Odink RJ, Hümmelink R, Partsch CJ, Sippell WG

Acta paediatrica Scandinavica. Supplement1 Jan 1991Cited by 21 (Europe PMC)

PMID1833950DOI10.1111/j.1651-2227.1991.tb17967.xPepBankPUB-01833950

Publisher page PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study7

7 results from studies that gave the peptide. 7 results from people.

01HumanNon-randomized trialEfficacy outcome
In children with central precocious puberty, height velocity stabilized at 4.0 cm/year after 3 years of triptorelin.
In plain wordsIn children with early puberty, growth stabilized at 4.0 cm/year after 3 years of triptorelin.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableHeight velocity during treatment
Study
n = 19
Outcome group
Linear growth · Endocrine and hormones
Studied dose
Dose not stated · 4 yearsAs given in this study (human).
Measurements
Height velocity
4 cm/year
after 3 years
Source sentences
Summary
After 3 years of treatment, height velocity stabilized at 4.0 cm/year.
1 context sentence(design, population, supporting numbers)
Summary · context
As part of an ongoing international multicentre study, 19 children (14 girls, 5 boys) with central precocious puberty (CPP) were treated with a slow-release gonadotrophin-releasing hormone (GnRH) agonist, triptorelin, for 4 years.
Report a problemFND-0183395001
02HumanNon-randomized trialEfficacy outcome
In girls with central precocious puberty, predicted adult height increased during triptorelin treatment.
In plain wordsIn girls with early puberty, predicted adult height increased during triptorelin treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreasePredicted adult height in girls
Study
n = 14
Outcome group
Linear growth · Endocrine and hormones
Studied dose
Dose not stated · 4 yearsAs given in this study (human).
Measurements
Predicted adult height
158.9 cm
before
Predicted adult height
164.9 cm
after
Source sentences
Summary
Predicted adult height (mean +/- SD) increased from 158.9 +/- 6.8 to 164.9 +/- 6.6 cm in girls (n = 14, p less than 0.01), and from 174.4 +/- 18.5 to 184.3 +/- 17.1 cm in boys (n = 4, p less than 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
As part of an ongoing international multicentre study, 19 children (14 girls, 5 boys) with central precocious puberty (CPP) were treated with a slow-release gonadotrophin-releasing hormone (GnRH) agonist, triptorelin, for 4 years.
Report a problemFND-0183395002
03HumanNon-randomized trialEfficacy outcome
After triptorelin cessation, menses began in all but one of the additional girls, at a mean of 9.8 months.
In plain wordsAfter triptorelin stopped, periods began in all but one of the additional girls, at a mean of 9.8 months.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
Not applicableMenses after discontinuation
Study
n = 12
Outcome group
Sex hormones and fertility · Reproductive and sexual health
Studied dose
Dose not stated · 2.2 +/- 0.5 yearsAs given in this study (human).
Measurements
Time to menses after cessation
9.8 months
12 additional girls after stopping triptorelin
Source sentences
Summary
In 12 additional girls who had started the multicentre study but discontinued triptorelin treatment after 2.2 +/- 0.5 years, menses started 9.8 +/- 3.7 months after cessation of treatment in all but one patient.
1 context sentence(design, population, supporting numbers)
Summary · context
As part of an ongoing international multicentre study, 19 children (14 girls, 5 boys) with central precocious puberty (CPP) were treated with a slow-release gonadotrophin-releasing hormone (GnRH) agonist, triptorelin, for 4 years.
Report a problemFND-0183395004
04HumanNon-randomized trialEfficacy outcome
In additional girls, height velocity increased after triptorelin cessation, remained above pretreatment values in the second half-year, then decreased.
In plain wordsIn additional girls, growth increased after triptorelin cessation, remained above pretreatment values in the second half-year, then decreased.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
MixedHeight velocity after discontinuation
Study
n = 12
Outcome group
Linear growth · Endocrine and hormones
Studied dose
Dose not stated · 2.2 +/- 0.5 yearsAs given in this study (human).
Measurements
Height velocity
3.6 cm/year
before cessation
Height velocity
5.4 cm/year
first 6 months after cessation
Source sentences
Summary
Height velocity increased over the first 6 months after discontinuation of treatment, from 3.6 +/- 0.1 to 5.4 +/- 2.5 cm/year, and remained higher than pretreatment values in the second 6 months, but decreased subsequently.
2 context sentences(design, population, supporting numbers)
Summary · context
In 12 additional girls who had started the multicentre study but discontinued triptorelin treatment after 2.2 +/- 0.5 years, menses started 9.8 +/- 3.7 months after cessation of treatment in all but one patient.
Summary · context
As part of an ongoing international multicentre study, 19 children (14 girls, 5 boys) with central precocious puberty (CPP) were treated with a slow-release gonadotrophin-releasing hormone (GnRH) agonist, triptorelin, for 4 years.
Report a problemFND-0183395005
05HumanNon-randomized trialEfficacy outcome
In additional girls with central precocious puberty, bone maturation increased after triptorelin cessation.
In plain wordsIn additional girls with early puberty, bone maturation increased after triptorelin stopped.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreaseBone maturation after discontinuation
Study
n = 12
Outcome group
Linear growth · Endocrine and hormones
Studied dose
Dose not stated · 2.2 +/- 0.5 yearsAs given in this study (human).
Source sentences
Summary
Bone maturation increased, and no significant improvement in predicted adult height was observed.
3 context sentences(design, population, supporting numbers)
Summary · context
In 12 additional girls who had started the multicentre study but discontinued triptorelin treatment after 2.2 +/- 0.5 years, menses started 9.8 +/- 3.7 months after cessation of treatment in all but one patient.
Summary · context
Height velocity increased over the first 6 months after discontinuation of treatment, from 3.6 +/- 0.1 to 5.4 +/- 2.5 cm/year, and remained higher than pretreatment values in the second 6 months, but decreased subsequently.
Summary · context
As part of an ongoing international multicentre study, 19 children (14 girls, 5 boys) with central precocious puberty (CPP) were treated with a slow-release gonadotrophin-releasing hormone (GnRH) agonist, triptorelin, for 4 years.
Report a problemFND-0183395006
06HumanNon-randomized trialEfficacy outcome
In additional girls, predicted adult height did not significantly improve after triptorelin cessation.
In plain wordsIn additional girls, predicted adult height did not significantly improve after triptorelin stopped.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
No significant changePredicted adult height after discontinuation
Study
n = 12
Outcome group
Linear growth · Endocrine and hormones
Studied dose
Dose not stated · 2.2 +/- 0.5 yearsAs given in this study (human).
Source sentences
Summary
Bone maturation increased, and no significant improvement in predicted adult height was observed.
3 context sentences(design, population, supporting numbers)
Summary · context
In 12 additional girls who had started the multicentre study but discontinued triptorelin treatment after 2.2 +/- 0.5 years, menses started 9.8 +/- 3.7 months after cessation of treatment in all but one patient.
Summary · context
Height velocity increased over the first 6 months after discontinuation of treatment, from 3.6 +/- 0.1 to 5.4 +/- 2.5 cm/year, and remained higher than pretreatment values in the second 6 months, but decreased subsequently.
Summary · context
As part of an ongoing international multicentre study, 19 children (14 girls, 5 boys) with central precocious puberty (CPP) were treated with a slow-release gonadotrophin-releasing hormone (GnRH) agonist, triptorelin, for 4 years.
Report a problemFND-0183395007
07HumanNon-randomized trialEfficacy outcome
In boys with central precocious puberty, predicted adult height increased during triptorelin treatment.
In plain wordsIn boys with early puberty, predicted adult height increased during triptorelin treatment.
Peptide
Triptorelin (Trelstar, Decapeptyl)
Outcome
IncreasePredicted adult height in boys
Study
n = 4
Outcome group
Linear growth · Endocrine and hormones
Studied dose
Dose not stated · 4 yearsAs given in this study (human).
Measurements
Predicted adult height
174.4 cm
before
Predicted adult height
184.3 cm
after
Source sentences
Summary
Predicted adult height (mean +/- SD) increased from 158.9 +/- 6.8 to 164.9 +/- 6.6 cm in girls (n = 14, p less than 0.01), and from 174.4 +/- 18.5 to 184.3 +/- 17.1 cm in boys (n = 4, p less than 0.05).
1 context sentence(design, population, supporting numbers)
Summary · context
As part of an ongoing international multicentre study, 19 children (14 girls, 5 boys) with central precocious puberty (CPP) were treated with a slow-release gonadotrophin-releasing hormone (GnRH) agonist, triptorelin, for 4 years.
Report a problemFND-0183395003

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:26 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.